(Press-News.org) (ORLANDO, Dec. 9, 2025) –– When hospitals were randomly assigned to treat patients undergoing higher-risk non-cardiac surgery with tranexamic acid (TXA) or a placebo, patients who received TXA needed significantly fewer blood transfusions and saw no increase in potentially life-threatening blood clots (thrombosis) after 90 days of follow-up, according to research presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
“Our findings confirm that TXA reduces the need for blood transfusion in patients undergoing higher-risk non-cardiac surgery,” said lead study author Brett Houston, MD, PhD, an assistant professor at the University of Manitoba and a scientist with the Paul Albrechtsen Research Institute in Winnipeg, Canada. “We were also able to show that giving TXA is safe and does not increase the occurrence of dangerous blood clots within the three-month high-risk period after surgery.”
TXA is a generic drug that promotes blood clotting, which is essential to stop blood loss from injuries or during surgery. However, a blood clot can be life threatening when it forms inside a blood vessel and blocks blood flow to vital organs.
A 2019 international study of 40,000 patients found major bleeding to be the most common life-threatening complication following non-cardiac surgery. Another large international randomized trial, known as POISE-3, showed that, compared with patients who received a placebo, patients who received TXA immediately before and after non-cardiac surgery had significantly less serious bleeding and needed fewer blood transfusions, with no significant increase in heart attacks, strokes, or blood clots at 30 days.
The current study, known as TRACTION, was designed to build on the findings of POISE-3, Dr. Houston said. Participating hospitals – 10 medical centers in Canada – were randomly assigned to administer either TXA or a placebo to adult patients undergoing major non-cardiac surgical procedures that posed an elevated risk for post-surgical bleeding complications and blood clots. Every four weeks, hospitals in the TXA group switched to the placebo group and vice versa.
Patients received a first dose of TXA or the placebo intravenously within minutes of surgery initiation. At the discretion of the attending anesthesiologist, they then received a second dose either at the conclusion of the operation or as a continuous infusion throughout the procedure.
The study’s primary endpoints were the number of patients needing blood transfusions during their hospital stay and the number diagnosed with blood clots within 90 days.
Secondary endpoints included the number of units of blood transfused; the number of patients diagnosed with a heart attack, stroke, or blood clot while in the hospital; the number of patients admitted to intensive care; the number surviving at 90 days after surgery; and patients’ length of stay in the hospital.
The study’s results are based on the evaluation of 8,273 patients treated across the 10 participating hospitals. More than 60% of the patients underwent cancer surgery. Among patients treated with TXA, 7.4% received a blood transfusion while in the hospital compared with 9.8% of those treated with the placebo, a statistically significant difference. Patients treated with TXA needed significantly fewer units of blood (0.34 units on average) than those in the placebo group (2.5 units on average). The proportion of patients diagnosed with blood clots within 90 days was the same (2.1%) in both the TXA and placebo groups. No significant differences were seen in any of the secondary endpoints.
The finding that TXA use does not increase risk for blood clots during the 90-day post-surgical period of elevated risk may reassure many practitioners who have previously been hesitant to adopt the drug, Dr. Houston said. “We hope this data will also set practitioners’ minds at rest that giving the drug is safe,” she said.
Although the study was limited to Canada, it evaluated bleeding risk across a broad range of types of higher-risk non-cardiac surgery, Dr. Houston said, including gynecologic, urologic, spinal, blood-vessel, and cancer surgery. In addition, participating hospitals included both academic medical centers and community hospitals.
A limitation of the study is that participation was restricted to hospitals with sophisticated electronic medical records systems in place to transmit study data.
Findings from other studies suggest that the use of TXA could be successfully introduced as a hospital-level policy in the same way that other surgical safety practices, such as antibiotic administration to prevent infection and the use of surgical checklists have been adopted, Dr. Houston said. As a next step, she and her colleagues plan to work on educating physicians about the TRACTION findings and promoting the adoption of TXA administration as a standard practice during higher-risk non-cardiac surgery.
This study was funded by the Canadian Institutes of Health Research, the Health Sciences Centre Foundation of Manitoba, and the health ministries of the Canadian provinces of Manitoba and Ontario.
Brett Houston, MD, PhD, of the University of Manitoba, will present this study on Tuesday, December 9, 2025, at 8:30 a.m. Eastern time during the Late-Breaking Abstracts Session in West Hall D2 of the Orange County Convention Center.
###
The American Society of Hematology (ASH) (hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. Join the #Fight4Hematology by visiting hematology.org/fight4hematology.
The Blood journals (https://ashpublications.org/journals) are the premier source for basic, translational, and clinical hematologic research. The Blood journals publish more peer-reviewed hematology research than any other academic journals worldwide.
END
Drug reduced need for blood transfusions during hospitalization for non-cardiac surgery
2025-12-09
ELSE PRESS RELEASES FROM THIS DATE:
Novel agent ianalumab added to standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia
2025-12-09
(ORLANDO, Dec. 9, 2025) Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or needing another treatment for their ITP, compared with patients who received a placebo in addition to standard therapy. The study is the first to test a novel drug for ITP early in the disease course and was presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
“In patients for whom first-line therapy had stopped working, treatment ...
Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL
2025-12-09
(ORLANDO, Dec. 9, 2025) – In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data were presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
“We were able to prove that pirtobrutinib is an excellent drug both in terms of efficacy and tolerance,” ...
Online tracking and privacy on hospital websites
2025-12-09
Researchers find that tracking pixels—small pieces of embedded code that can transmit user data to third parties—significantly increase data breach risk on hospital websites. Hilal Atasoy and colleagues analyzed 12 years of archived website data from 1,201 large US hospitals between 2012 and 2023, examining the adoption of pixel tracking and their relationship to data breaches. The authors found pixel tracking in 66% of hospital-year observations, despite stringent privacy regulations. Hospitals using third-party pixels experienced at least a 1.4 percentage point increase in breach probability, representing a 46% ...
A freely available tool to document wartime destruction
2025-12-09
Researchers develop a method to detect the destruction of buildings using freely available satellite radar imagery. Daniel Racek and colleagues’ algorithm analyzes publicly available Sentinel-1 synthetic aperture radar images from the European Space Agency to identify destroyed buildings in conflict zones. The method statistically assesses the visual similarity of locations over time, enabling detection of destruction from a single satellite image every 12 days, without requiring labeled training data or expensive proprietary imagery. Unlike optical ...
Residential solar panels can raise electricity rates
2025-12-09
A modeling study shows how under some conditions, increasing numbers of households with rooftop solar panels can lead to higher rates for those without their own solar system. When utility customers cancel their accounts after switching to residential solar panels, the utility must spread their fixed costs around to a smaller number of remaining customers, which can lead to rate increases. Charles Sims and colleagues studied how this pecuniary externality affects different income groups using agent-based computational economic modeling of the Tennessee Valley Authority (TVA), an area with some of the highest poverty rates in the United States. The authors asked 2,307 TVA residential customers ...
Scientists use synthetic platelets as ‘Trojan horse’ drug-delivery system
2025-12-09
CLEVELAND—Scientists working to enhance brain-computer interface (BCI) technology—which allows people to control devices with their thoughts—have found they can improve the performance of electrodes implanted in the brain by targeted delivery of anti-inflammatory drugs.
Case Western Reserve University researchers, in collaboration with Haima Therapeutics, used a novel “platelet-inspired nanoparticle” to deliver an anti-inflammatory drug directly to where BCI electrodes were implanted. The drug doubled the effectiveness of ...
Cooperative Intermolecular Interactions Regulate Supramolecular Polymer Assembly
2025-12-09
Supramolecular chemistry involves the study of self-assembly of discrete molecules that are used to build functional large structures. Often, these molecules are allowed to self-assemble into one-dimensional polymeric structures (supramolecular polymers or SPs) in a suitable environment, and the dynamic molecular interactions are noted for tweaking the environment and improving the features of the resulting SPs. They are being explored as the next-generation polymeric materials with applications in electronics, soft-robotics, ...
Korea University researchers develop ultrasensitive method to detect low-frequency cancer mutations
2025-12-09
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.
To address this challenge, researchers led by Professor Junseok W Hur from Korea University College of Medicine, in collaboration with multiple partners, have developed MUTE-Seq, a highly sensitive CRISPR-based method designed to detect cancer mutations present at exceptionally low frequencies while simultaneously reducing sequencing costs and background error noise. The study was first made available ...
First patient enrolled in GOG-3133/ FRAmework-01 phase 3 study evaluating sofetabart mipitecan (LY4170156), a novel ADC targeting folate receptor alpha (FRα), in recurrent ovarian cancer
2025-12-09
Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart Mipitecan (LY4170156), a Novel ADC Targeting Folate Receptor Alpha (FRα), in Recurrent Ovarian Cancer
The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3133, a pivotal Phase 3 clinical trial titled FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. The study is sponsored by Eli ...
Two Hebrew University researchers win prestigious ERC consolidator grants
2025-12-09
The Hebrew University of Jerusalem proudly congratulates two of its esteemed researchers on receiving the prestigious European Research Council (ERC) Consolidator Grant for 2025. Both awardees, who lead groundbreaking work in applied physics and international relations, were selected for one of Europe’s most competitive grants, awarded to researchers 7–12 years after their doctorates. These grants support the establishment of independent research groups, the development of new laboratories, and innovative projects across the natural sciences, social sciences, and humanities. This recognition continues the university’s ...